In 2015, NICE said that BioMarin's Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome ... which works by replacing a missing enzyme that is needed to break ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback